PLos One:使用顺铂 vs.卡铂治疗肺癌的血栓栓塞风险比较

2017-12-12 xiangting MedSci原创

肺癌患者中卡铂相关性TEEs的发生率高,顺铂和卡铂组间出现TEEs的风险没有显著差异。

卡铂在美国作为顺铂的替代物被广泛用于肺癌的治疗。一些研究已经证实,基于顺铂的方案与血栓栓塞并发症的发生率高有关。然而,直接比较顺铂和卡铂治疗的肺癌患者血栓栓塞事件(TEE)风险的研究却很有限。

研究纳入2011至2014年在Rochester大学Wilmot癌症中心接受顺铂或卡铂治疗的所有肺癌患者。通过回顾电子病历收集包括暴露情况(顺铂vs.卡铂)和结局(初次使用顺铂或卡铂与最后一次使用后4周之间的TEEs)的患者特征。使用Fisher精确检验来比较顺铂和卡铂组之间的偶发TEEs比例。使用多重logistic回归评估与顺铂vs.卡铂相关的TEE风险。

在415例受试者中,317例(76.4%)接受卡铂,98例(23.6%)接受顺铂治疗。在卡铂组中,10.9%(33/302)的可评估患者出现治疗相关性TEEs,而顺铂组为14.7%(14/95)。两组出现TEEs的风险差异无显著意义(P = 0.32)。然而,与卡铂相关的TEEs中有15.2%是动脉血栓形成,而顺铂组中则没有动脉血栓。

肺癌患者中卡铂相关性TEEs的发生率高,顺铂和卡铂组间出现TEEs的风险没有显著差异。对所有铂类治疗的患者预防性应用抗凝剂的可能性仍需要进一步研究。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1790087, encodeId=222a1e9008767, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Sat Jun 09 00:39:00 CST 2018, time=2018-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078451, encodeId=713c20e845136, content=<a href='/topic/show?id=1842100886df' target=_blank style='color:#2F92EE;'>#风险比#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100886, encryptionId=1842100886df, topicName=风险比)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Wed Sep 19 15:39:00 CST 2018, time=2018-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1737547, encodeId=c09e1e375477b, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96575, encryptionId=292f965e5b5, topicName=铂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca4034296500, createdName=ms3153534357578991, createdTime=Sat Jun 23 02:39:00 CST 2018, time=2018-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=271378, encodeId=5fe12e137888, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Fri Dec 22 05:42:58 CST 2017, time=2017-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396285, encodeId=1f69139628506, content=<a href='/topic/show?id=9dc636545a4' target=_blank style='color:#2F92EE;'>#卡铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36545, encryptionId=9dc636545a4, topicName=卡铂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Thu Dec 14 05:39:00 CST 2017, time=2017-12-14, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1790087, encodeId=222a1e9008767, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Sat Jun 09 00:39:00 CST 2018, time=2018-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078451, encodeId=713c20e845136, content=<a href='/topic/show?id=1842100886df' target=_blank style='color:#2F92EE;'>#风险比#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100886, encryptionId=1842100886df, topicName=风险比)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Wed Sep 19 15:39:00 CST 2018, time=2018-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1737547, encodeId=c09e1e375477b, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96575, encryptionId=292f965e5b5, topicName=铂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca4034296500, createdName=ms3153534357578991, createdTime=Sat Jun 23 02:39:00 CST 2018, time=2018-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=271378, encodeId=5fe12e137888, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Fri Dec 22 05:42:58 CST 2017, time=2017-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396285, encodeId=1f69139628506, content=<a href='/topic/show?id=9dc636545a4' target=_blank style='color:#2F92EE;'>#卡铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36545, encryptionId=9dc636545a4, topicName=卡铂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Thu Dec 14 05:39:00 CST 2017, time=2017-12-14, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1790087, encodeId=222a1e9008767, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Sat Jun 09 00:39:00 CST 2018, time=2018-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078451, encodeId=713c20e845136, content=<a href='/topic/show?id=1842100886df' target=_blank style='color:#2F92EE;'>#风险比#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100886, encryptionId=1842100886df, topicName=风险比)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Wed Sep 19 15:39:00 CST 2018, time=2018-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1737547, encodeId=c09e1e375477b, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96575, encryptionId=292f965e5b5, topicName=铂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca4034296500, createdName=ms3153534357578991, createdTime=Sat Jun 23 02:39:00 CST 2018, time=2018-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=271378, encodeId=5fe12e137888, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Fri Dec 22 05:42:58 CST 2017, time=2017-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396285, encodeId=1f69139628506, content=<a href='/topic/show?id=9dc636545a4' target=_blank style='color:#2F92EE;'>#卡铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36545, encryptionId=9dc636545a4, topicName=卡铂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Thu Dec 14 05:39:00 CST 2017, time=2017-12-14, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1790087, encodeId=222a1e9008767, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Sat Jun 09 00:39:00 CST 2018, time=2018-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078451, encodeId=713c20e845136, content=<a href='/topic/show?id=1842100886df' target=_blank style='color:#2F92EE;'>#风险比#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100886, encryptionId=1842100886df, topicName=风险比)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Wed Sep 19 15:39:00 CST 2018, time=2018-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1737547, encodeId=c09e1e375477b, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96575, encryptionId=292f965e5b5, topicName=铂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca4034296500, createdName=ms3153534357578991, createdTime=Sat Jun 23 02:39:00 CST 2018, time=2018-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=271378, encodeId=5fe12e137888, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Fri Dec 22 05:42:58 CST 2017, time=2017-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396285, encodeId=1f69139628506, content=<a href='/topic/show?id=9dc636545a4' target=_blank style='color:#2F92EE;'>#卡铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36545, encryptionId=9dc636545a4, topicName=卡铂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Thu Dec 14 05:39:00 CST 2017, time=2017-12-14, status=1, ipAttribution=)]
    2017-12-22 1e145228m78(暂无匿称)

    学习了谢谢作者分享!

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1790087, encodeId=222a1e9008767, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Sat Jun 09 00:39:00 CST 2018, time=2018-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078451, encodeId=713c20e845136, content=<a href='/topic/show?id=1842100886df' target=_blank style='color:#2F92EE;'>#风险比#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100886, encryptionId=1842100886df, topicName=风险比)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Wed Sep 19 15:39:00 CST 2018, time=2018-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1737547, encodeId=c09e1e375477b, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96575, encryptionId=292f965e5b5, topicName=铂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca4034296500, createdName=ms3153534357578991, createdTime=Sat Jun 23 02:39:00 CST 2018, time=2018-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=271378, encodeId=5fe12e137888, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Fri Dec 22 05:42:58 CST 2017, time=2017-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396285, encodeId=1f69139628506, content=<a href='/topic/show?id=9dc636545a4' target=_blank style='color:#2F92EE;'>#卡铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36545, encryptionId=9dc636545a4, topicName=卡铂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Thu Dec 14 05:39:00 CST 2017, time=2017-12-14, status=1, ipAttribution=)]

相关资讯

胸外专题:机器人辅助肺癌支气管袖式切除术

支气管袖式切除术是治疗中央型肺癌的最佳手术方式,但多数需要开胸手术才能完成。本文探讨机器人辅助肺癌支气管袖式切除术的可行性和手术方案。

早期肺癌外科治疗策略

随着胸部CT肺癌筛查项目的开展和百姓健康体检意识的增强,大量的低剂量螺旋CT被应用于肺癌筛查项目中,更多的肺内小结节患者走进我们的视野。这虽然可以使更多的早期肺癌患者通过微创外科手术得以根治治疗,但目前存在的过度诊断和过度治疗引起了胸外科学界和肿瘤学界的关注与担忧。

病例分享:“峰回路转”的1例肺癌患者治疗

患者女性,46岁,主因“咳嗽伴右侧肋部疼痛2月余”于2013年1月14日就诊我科。

王洁教授:肺癌液体活检的进展和未来

现今晚期NSCLC已进入了以分子分型为基础的个体化精准靶向治疗时代,精准治疗首先需要精准的分子分型,但不是每个患者都可顺利获得合格的肿瘤组织标本,于是液态活检应运而生。回顾性研究证实血浆ctDNA EGFR突变与组织EGFR突变在指导NSCLC靶向治疗上具有较好的一致性。王洁教授主持的BENEFIT研究首次前瞻性证实了液体活检指导一线TKI疗效的可行性,血检阳性患者一线选择吉非替尼,ORR 72.

JNCI:左右互搏-不吸烟人群肺癌的发病率上升了吗?

在今年由美国学者发起的研究发现,在过去的二十年,不吸烟人群中非小细胞肺癌(NSCLC)的发病率翻了一番。而由澳大利亚学者发起的最新一项研究却得出了不一致的结论。

重复 Cell:肺癌患者的希望!两药联合应用可能会增加肺癌患者的免疫治疗反应

约翰霍普金斯Kimmel癌症中心的研究人员和同事们已经确定了一种新型的药物联合疗法,可以使非小细胞肺癌更好地应对免疫治疗。这些所谓的表观遗传治疗药物一起使用,在人癌细胞系和小鼠中实现了强大的抗肿瘤应答。